PARP the perpetrator; Chemokines in the spotlight; New life for tobacco

Guilford Pharmaceuticals Inc. demonstrated proof-of-principle for its stroke program in a Nature Medicine paper showing that mice deficient in an enzyme called poly(ADP-ribose) polymerase (PARP) are resistant to neurotoxicity and have reduced infarct volume after a stroke.

The work was done by scientists at Johns Hopkins University, which has granted GLFD (Baltimore, Md.) exclusive license to the use of PARP inhibitors to prevent neurotoxicity.

The Hopkins researchers showed that PARP activity was required for neurotoxicity induced by the neurotransmitter NMDA or the signaling molecule nitric oxide (NO). Cells from homozygous knockout mice (completely lacking PARP) were completely resistant to such toxicity, and cells from heterozygous mice (with only one copy of PARP instead of two) were 73 percent resistant.

In

Read the full 1179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE